Arrowhead Pharmaceuticals is, on paper, a development-stage biotech with a $194.3 million quarterly net loss. In practice, the company is something stranger and more interesting: a clinical-stage RNAi platform that simultaneously launched its first commercial product, REDEMPLO, for the ultra-rare familial chylomicronemia syndrome; reported positive Phase 3 topline data for the same molecule in the much larger severe hypertriglyceridemia population; collected $25.0 million upfront from Madrigal for an MASH-targeted candidate the company had not previously disclosed a partner for; and ended the quarter with $1,566.9 million of cash and available-for-sale securities and total liabilities of $1,646.0 million that include a $700.0 million zero-coupon convertible maturing in 2032 at a $30.00 strike with a $119.33 capped-call ceiling. The market cap is $12.08 billion at the $85.59 reference price. Once the convertible is netted against cash, the company is functionally a commercial-stage launch with a $4.0 billion dollar-for-dollar embedded option on its own equity sitting 39% above the current price.
The single number the market is mis-pricing is the balance sheet, not the pipeline. Vendor screens still bucket ARWR with clinical-stage burn stories, where the multiple is some version of price-to-cash-plus-milestones. The corrected read is that the cash and short-term securities alone of $1.57 billion, less the convert face of $700.0 million, leaves $866.9 million of net liquidity - roughly $6.14 per fully-issued share - before any milestone receivable, royalty stream, or commercial profit is counted. The stock trades at $85.59. Either the company is being valued as if the cash will be spent on a Phase 3 program management has not guided for, or the market is mis-pricing the convert's dilution risk. Management's own "transformational events" language in the Q3 release says the same thing from the other side of the trade.
The quarter's GAAP numbers will not help: revenue of $75.3 million was up 171% year over year on a low base, but the first half of the fiscal year carried the bulk of the Sarepta milestone receipts and Q3 reflects the lag between the last big milestone and the next. The nine-month view is the right period to read: total operating expenses grew 31.8% to $683.6 million, with R&D up 26.9% to $548.7 million and selling, general and administrative up 56.4% to $134.9 million as the REDEMPLO launch built out. The operating loss for the nine months was $(270.5) million versus $54.2 million of operating income a year ago, and the net loss attributable to Arrowhead of $194.3 million in Q3 was the largest in the company's history. The cash use stayed modest because partnerships front-load receipts: net cash used in operations for the nine months was $79.5 million, while the company raised a net $681.3 million from the January convertible and $216.6 million from a concurrent follow-on plus pre-funded warrants.
The thesis for the next twelve months is not a single product but a portfolio of partner-funded readouts and a small commercial launch that is doubling prescription volume each quarter from a tiny base. The thesis against is that the operating loss is widening as commercial spending scales ahead of revenue, the convert is unambiguously a dilution cap at higher prices, and the net-cash position is what makes the equity interesting at all.